Clinical and In Vitro Safety of Heyndrickxia coagulans AO 1167B: A Double-Blind, Placebo-Controlled Trial

Gissel García, Josanne Soto, Antonio Díaz, Jesús Barreto, Carmen Soto, Ana Beatriz Pérez, Suselys Boffill, Ángela Gutiérrez, Raúl de Jesús Cano · 2024

Read Clinical and In Vitro Safety of Heyndrickxia coagulans AO 1167B: A Double-Blind, Placebo-Controlled Trial by Gissel García, Josanne Soto, Antonio Díaz, Jesús Barreto, Carmen Soto, Ana Beatriz Pérez, Suselys Boffill, Ángela Gutiérrez, Raúl de Jesús Cano (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677179.txt.

Description

Gissel García and colleagues put a candidate probiotic bacterium through a full safety workout, in this trial from twenty twenty-four. The strain, Heyndrickxia coagulans AO 1167B, makes lactic acid and straddles two bacterial families in its traits. Early evidence hints at gut benefits, but a supplement must first prove it is harmless.

The team sequenced the strain's genome and found no worrying resistance or toxin genes. Dish tests showed no drug resistance, no damage to cells, and no bursting of blood cells. Then came a phase one trial: healthy adults took the strain or a dummy capsule for sixty days, with neither side knowing which. Blood tests and health checks stayed level in both groups. Gas was the commonest complaint and faded with time. The authors judge the strain safe enough to earn deeper clinical study.

Catalog record

CREATORGissel García, Josanne Soto, Antonio Díaz, Jesús Barreto, Carmen Soto, Ana Beatriz Pérez, Suselys Boffill, Ángela Gutiérrez, Raúl de Jesús Cano
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11677179

Browse the full library · About the Tower of Babel